whether this holds also true for t(12;21)-positive ALL and whether we are able to discriminate between children, who are likely to be cured from those, who are at risk for a relapse.
In the present study, we selected 57 children with B cell precursor (BCP) ALL according to the availability of bone marrow samples at diagnosis, during the course of therapy and at relapse. Eight patients had high risk leukemia according to BFM criteria (prednisone poor response, t(4;11), or t(9;22)). None of the prednisone poor responders had a t(12;21)-positive leukemia and they were therefore excluded from further analysis. The remaining 49 children with non-high risk BCP ALL were treated in Austria according to current BFM protocols 4 (ALL-BFM 90: n = 43, ALL-BFM 95: n = 6) between January 1992 and November 1996. Age at diagnosis ranged from 3 months to 14 years (median 5 years). Clinical characteristics of the patients did not deviate from those of the additional 189 children with non-high risk BCP-ALL enrolled in the ALL-BFM studies in Austria during the study period. To increase the number of relapses from t(12;21)-positive leukemias two additional patients with a late relapse of their t(12;21)-positive ALL, one isolated in the ovary after 4.1 years and the other in the bone marrow after 4.5 years, from whom follow-up samples for MRD analysis were available, have been included.
After the identification of leukemia clone-specific antigen receptor gene rearrangements (IGH, IGK, TCRD, TCRG) in DNA from diagnostic bone marrow mononuclear cells junctional region specific oligonucleotides were designed for dot blot hybridization of PCR amplified DNA from follow-up samples, as described previously. [2] [3] [4] The amount of residual leukemia was estimated by comparing the signal of the follow-up sample with a log dilution of bone marrow cells from diagnosis. A sensitivity of at least 10 −4 was required for inclusion in this study. The patients were assigned to three different MRD risk groups that were based on the combined information of the MRD levels after 5 weeks of induction (time point 1) and before the start of consolidation treatment, 12 weeks after diagnosis (time point 2). In the low risk (LR) group, MRD was already negative at time point 1. The leukemia burden in the intermediate risk (IR) group was lower than 10 −3 at time point 2 and the high risk (HR) group had a persistent high leukemia load equal to or more than 10 −3 at time point 2.
2 Diagnosis of a t(12;21) was made by dual-color FISH on methanol/acetic acid fixed material according to standard methods with two cosmids (50F4 and cos664) that are specific for the TEL and the AML1 locus, respectively. Two hundred nuclei of each sample were evaluated. Fifteen out of 49 children with non-high risk BCP ALL had a t(12;21)-positive ALL (30.6%). These children were younger at diagnosis (median 3.6 years, range 2-11.6 years) than those in the control group (median 5.4 years, range 0.3-14 years). After a median observation time of 6.1 years (range 3-7.9 years), three systemic relapses occurred in the t(12;21)-positive group (after 1.6 years, 1.8 years and 2.8 years, respectively). In all three instances the TEL-AML1 fusion was detected at diagnosis as well as in the relapse sample. There were five systemic relapses in the control group after a remission duration of 5.1 years (median, range 0.3-7.8 years). This relapse rate of approximately 20% in both groups is in line with large retrospective and prospective studies reported by various groups who use BFM-based treatment protocols, but is significantly higher than those reported from the USA. 1 The distribution of the 49 children in the two different risk-adapted treatment groups (BFM RG; Table 1 ) corresponds with that of larger series of patients. 5 To better define the individual risk of patients with a t(12;21)-positive ALL, we determined MRD from bone marrow samples during the first 3 months of treatment. As demonstrated earlier, the MRD levels at these two time points are very useful to discriminate between children who are likely to be cured (MRD-LR), from those with a 23% (MRD-IR) and a 75% (MRD-HR) risk of relapse at 3 years, respectively. 2 The fact that all five patients with a relapse of their t(12;21)-positive ALL were in the MRD-IR (three late relapses and one early relapse) and MRD-HR groups (the other early relapse), and no relapses occurred in the MRD-LR group confirms the predictive value of early MRD evaluation also in this particular subgroup of ALL (three patients with relapses from the study population are shown in Table 1 , the additional two patients with a relapse were selected, and therefore not included in the Table) . Persisting or reappearing low levels of MRD as detected by Zuna et al 6 by RT-PCR were not detected in patients from our study, who remained in complete continuous remission. The prognostic significance of low levels MRD in the former study needs to be evaluated after a longer observation time. The comparison of MRD levels detected by clonotypic antigen receptor gene rearrangements and by RT-PCR of TEL-AML1 fusion products could provide some significant clues with regard to their biological and prognostic significance and have been initiated. Although the data are preliminary because of the small number of patients with TEL-AML1-positive leukemias included in the study, they support the decision to stratify both patients with TEL-AML1-positive and TEL-AML1-negative leukemias according to MRD for treatment in the ongoing ALL-BFM study.
